Crop Life Science Ltd

Crop Life Scienc showed mixed financial performance from March 2024 to March 2025, with net sales increasing to 200.59 Cr and operating profit rising to 17.38 Cr, but profit after tax decreased to 5.60 Cr and cash flow from operations remained negative. Total assets and shareholder's funds grew, indicating some financial stability despite challenges in net profit and cash flow.

As of November 10, 2025, Crop Life Science is fairly valued with a PE Ratio of 13.98, an EV to EBITDA of 8.16, and a ROCE of 11.07%, outperforming the Sensex with an 11.92% return compared to its 5.91%, and is considered undervalued relative to peers like UPL and Dhanuka Agritech.

As of November 6, 2025, Crop Life Science is considered overvalued with a PE ratio of 13.98 and an EV to EBITDA of 8.16, despite a year-to-date return of 7.68%, which is slightly below the Sensex's 7.89%, indicating that investors may be paying a premium compared to its peers like UPL and Bayer CropScience.

As of October 20, 2025, Crop Life Science is fairly valued with a PE ratio of 14.24, an EV to EBITDA of 8.27, and a ROCE of 11.07%, making it more attractively priced than peers like UPL and P I Industries, while also outperforming the Sensex with a 10% return over the past year.

As of October 17, 2025, Crop Life Science is considered overvalued with a valuation grade of expensive, reflected by its PE ratio of 14.50 and EV to EBITDA of 8.38, especially when compared to peers like UPL and BASF India.

As of October 17, 2025, Crop Life Science is considered overvalued with a PE ratio of 14.50 and an EV to EBITDA of 8.38, despite a year-to-date return of 11.67%, which is not competitive compared to peers like UPL and Bayer CropScience.

As of October 17, 2025, Crop Life Science is considered overvalued with a PE Ratio of 14.50, significantly lower than peers like UPL and Bayer CropScience, despite a year-to-date return of 11.67%.

As of 26-Sep, Crop Life Science Ltd's stock price is at 56.20, down 7.11% and underperforming its sector. Despite a year-to-date increase of 12.06%, recent declines indicate unique pressures compared to the broader market.

As of 24-Sep, Crop Life Science Ltd is priced at 60.50 with a recent 1-week return of +0.83%, outperforming the Sensex's decline. However, a significant drop in delivery volume by 54.55% raises concerns about the sustainability of its performance despite a strong year-to-date return of +20.64%.

As of September 23, 2025, Crop Life Science is fairly valued with a PE ratio of 15.66 and an EV to EBITDA of 8.86, outperforming the Sensex with a year-to-date return of 20.64%.

As of 23-Sep, Crop Life Science Ltd is priced at 60.50, showing no change today but has gained 20.64% year-to-date, outperforming the Sensex. However, a 54.55% drop in delivery volume compared to the 5-day average raises concerns about future trading activity.

As of September 22, 2025, Crop Life Science is considered an attractive investment due to its undervalued status with a PE ratio of 15.66, an EV to EBITDA ratio of 8.86, a competitive PEG ratio of 1.63, and a year-to-date stock performance of 20.64%, significantly outperforming the Sensex's 6.59%.

As of 22-Sep, Crop Life Science Ltd is priced at 60.50 with no change, outperforming its sector by 1.25%. Despite a strong year-to-date increase of 20.64% and positive moving averages, a significant decline in delivery volume raises concerns about investor interest.

As of 19-Sep, Crop Life Science Ltd is priced at 60.50, showing a 0.75% increase and trading above all key moving averages. Despite a recent decline in investor participation, the stock has outperformed its sector and the broader market year-to-date.

As of September 18, 2025, Crop Life Science is fairly valued with a PE ratio of 15.55 and an EV to EBITDA of 8.82, outperforming the Sensex with a 19.74% return year-to-date, while its valuation remains competitive compared to peers like UPL and Rallis India.

As of 18-Sep, Crop Life Science Ltd's stock price is Rs 60.05, reflecting a slight increase of 0.08%. The stock has outperformed the sector and the benchmark Sensex year-to-date, indicating strong overall performance despite recent short-term challenges.

As of September 17, 2025, Crop Life Science is considered an attractive investment due to its undervalued financial ratios, including a PE Ratio of 15.53 and an EV to EBITDA of 8.81, which are significantly lower than peers like UPL and Bayer CropScience, despite recent underperformance against the Sensex.

As of 17-Sep, Crop Life Science Ltd's stock price is Rs 60.00, down 0.33%, and has underperformed its sector by 4.28%. Despite being close to its 52-week high, the stock has seen negative returns recently and a significant drop in investor participation, indicating reduced trading interest.

As of September 16, 2025, Crop Life Science's valuation has shifted from attractive to fair, with a PE Ratio of 15.59, an EV to EBITDA of 8.83, and a ROCE of 11.07%, positioning it competitively against peers like P I Industries and Bayer CropScience, while outperforming the Sensex with a year-to-date return of 20.04%.